Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Caficrestat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 known ✓ | P15121 | 20/20 | 0.81 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.73 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.73 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Caficrestat SCHEMBL29444132 | 1.00 | AKR1B1 (0.81) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL9204262 | 0.89 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL19726781 | 0.89 | AKR1B1 (0.66) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL9871941 | 0.89 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL15947498 | 0.89 | AKR1B1 (0.66) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL360713 | 0.88 | AKR1B1 (0.64) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL19140642 | 0.88 | AKR1B1 (0.65) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL362567 | 0.88 | AKR1B1 (0.71) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL20696585 | 0.87 | AKR1B1 (0.65) | AKR1B1AKR1B10AKR1A1GLO1 | |
| SCHEMBL24205815 | 0.87 | AKR1B1 (0.65) | AKR1B1AKR1B10AKR1A1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 481 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4694930-A1 | COMBINATION THERAPIES INVOLVING GREM1 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4695239-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4211136-B1 | SOLID STATE FORMS OF AT-001 AND PROCESS FOR PREPARATION THEREOF | ASSIA CHEM IND LTD (IL) | 2025-08-20 | — | — | EP | claimed |
| US-20250222024-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | REVERSPAH LLC (US) | 2025-07-10 | — | — | US | claimed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | claimed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | claimed |
| WO-2024213066-A1 | COMBINATION THERAPIES INVOLVING GREM1 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2024-10-17 | — | — | WO | claimed |
| WO-2024216034-A1 | DISUBSTITUTED PYRIMIDINE COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-10-17 | — | — | WO | claimed |
| CN-113896721-B | Nicotinamide phosphoribosyl transferase inhibitors with tumor targeting | 华东师范大学 | 2024-09-20 | — | — | CN | claimed |
| EP-4211136-A1 | SOLID STATE FORMS OF AT-001 AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2023-07-19 | — | — | EP | claimed |
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | EWHA WOMANS UNIVERSITY (KR) | 2023-07-13 | — | — | US | claimed |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | MEREO BIOPHARMA 4 LIMITED (GB) | 2023-07-13 | — | — | US | claimed |
| EP-4192472-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | Reverspah LLC (US) | 2023-06-14 | — | — | EP | claimed |
| CN-115803023-A | Method of treating patients infected with coronavirus with nerzetinib | 施万生物制药研发IP有限责任公司 | 2023-03-14 | — | — | CN | claimed |
| US-20230021647-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC | 2023-01-26 | — | — | US | claimed |
| WO-2022271604-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | claimed |
| WO-2022055836-A1 | SOLID STATE FORMS OF AT-001 AND PROCESS FOR PREPARATION THEREOF | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2022-03-17 | — | — | WO | claimed |
| WO-2022035813-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | REVERSPAH LLC (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220040227-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | REVERSPAH LLC (US) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218644-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY RESPIRATORY SYNDROME-RELATED CORONAVIRUS | ACE2, ACE, TMPRSS2 | AKR1B1 4584/4885AKR1B10 4256/4885AKR1A1 4541/4885 |
| US-20230021647-A1 | METHOD OF TREATING A PATIENT INFECTED WITH A CORONAVIRUS AND HAVING A BASELINE LEVEL OF CRP BELOW 150 MG/L | ALB, ACE, ACE2 | AKR1B1 1036/4885AKR1B10 1183/4885AKR1A1 898/4885 |
| US-20220040227-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | NFKBIA, ALOX15, ALOX15B | AKR1B1 35/4885AKR1B10 174/4885AKR1A1 51/4885 |
| US-20250222024-A1 | METHOD AND COMPOSITION FOR TREATING CORONA VIRUS, INFLUENZA, AND ACUTE RESPIRATORY DISTRESS SYNDROME | NFKBIA, ALOX15, ALOX15B | AKR1B1 35/4885AKR1B10 174/4885AKR1A1 51/4885 |
| US-20230218596-A1 | METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING CORONAVIRUS INFECTION | SERPINB1, ELANE, MPO | AKR1B1 2617/4885AKR1B10 3596/4885AKR1A1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.